Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 10/20 | 0.63 |
| ▸ | TP53 | P04637 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4221662 | 0.93 | ALDH1A1 (0.71) | ALDH1A1HTTMAPTTP53HPGD | |
| SCHEMBL4232736 | 0.89 | ALDH1A1 (0.69) | ALDH1A1HTTMAPTTP53HPGD | |
| SCHEMBL4223815 | 0.88 | ALDH1A1 (0.67) | ALDH1A1HTTMAPTTP53HPGD | |
| SCHEMBL4518533 | 0.88 | MAPT (0.76) | ALDH1A1HTTMAPTTP53HPGD | |
| SCHEMBL4224740 | 0.86 | MAPT (0.67) | ALDH1A1HTTMAPTTP53HPGD | |
| SCHEMBL13911398 | 0.86 | MAPT (0.76) | ALDH1A1HTTMAPTTP53HPGD | |
| SCHEMBL4234049 | 0.85 | MAPT (0.70) | ALDH1A1HTTMAPTTP53HPGD | |
| SCHEMBL4218366 | 0.84 | TP53 (0.60) | ALDH1A1HTTMAPTTP53HPGD | |
| SCHEMBL4228805 | 0.84 | ALDH1A1 (0.61) | ALDH1A1HTTMAPTTP53HPGD | |
| SCHEMBL4234753 | 0.84 | ALDH1A1 (0.61) | ALDH1A1HTTMAPTTP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | claimed |
| EP-2046795-A1 | FURO[3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | Amura Therapeutics Limited (GB) | 2009-04-15 | — | — | EP | disclosed |
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| EP-1994010-A1 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008007109-A1 | FURO[3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007104775-A1 | COMPOUNDS WHICH INHIBIT THE GLYCINE TRANSPORTER AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062360-A1 | Compounds Which Inhibit the Glycine Transporter and Uses Thereof | SLC18A2, SLC1A2, SLC1A1 | ALDH1A1 974/4885HTT 358/4885MAPT 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.